VIR Vir Biotechnology, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1706431 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY1,696.0%
TTM net income YoY63.0%
TTM EPS YoY67.4%
Revenue 3-yr CAGR36.6%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-69.8%
Net margin-61.0%
FCF margin-46.8%
EBITDA margin-66.1%
Returns
ROE-21.8%
ROA-17.3%
ROIC (approx.)-25.6%
Asset turnover0.28x
Leverage & solvency
Liabilities / assets19.4%
Debt / equity0.00x
Current ratio6.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.76x
Accruals ratio-4.1%
Payout ratio—
Capex / revenue0.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $68.56M | $74.20M |
| Cost of revenue | $26,000 | $845,000 |
| Gross profit | $68.53M | $73.36M |
| R&D expense | $455.97M | $506.50M |
| SG&A expense | $92.07M | $119.03M |
| Operating income | -$479.33M | -$587.16M |
| Pretax income | -$437.77M | -$523.11M |
| Income tax | $217,000 | -$1.15M |
| Net income | -$437.99M | -$521.96M |
| EBITDA | -$467.65M | -$572.61M |
| EPS (basic) | -3.16 | -3.83 |
| EPS (diluted) | -3.16 | -3.83 |
| Weighted avg. shares (diluted) | 138.52M | 136.25M |
| Balance sheet | ||
| Cash & equivalents | $232.19M | $318.69M |
| Short-term investments | $228.75M | $678.05M |
| Current assets | $514.08M | $1.04B |
| PP&E, net | $55.62M | $63.18M |
| Goodwill | $16.94M | $16.94M |
| Intangibles | $7.85M | $8.12M |
| Total assets | $1.00B | $1.40B |
| Current liabilities | $92.81M | $119.66M |
| Total liabilities | $237.55M | $248.43M |
| Shareholders' equity | $765.28M | $1.15B |
| Shares outstanding | 139.47M | 136.96M |
| Cash flow statement | ||
| Operating cash flow | -$391.78M | -$446.35M |
| Capital expenditure | $4.83M | $7.30M |
| Free cash flow | -$396.61M | -$453.65M |
| Investing cash flow | $310.37M | $499.37M |
| Financing cash flow | $3.79M | $4.39M |
| Depreciation & amortization | $11.68M | $14.56M |
| Stock-based compensation | $49.07M | $78.46M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.